Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Inclusion Criteria: * Age 18 years or above * Life Expectancy \> 3 months * Histologically confirmed diagnosis of PTCL * Patients with transformed CTCL eligible for CHOP regimen * Measurable disease based on Cheson 2007 criteria * Eastern Cooperative Oncology Group (ECOG) performance status \< 2 Exclusion Criteria: * Known active Hepatitis B/ Hepatitis C/ HIV infection * Known, uncontrolled CNS metastases or primary CNS lymphoma * Deep vein thrombosis diagnosed within 3 months * Ongoing treatment for pre-existing cardiovascular disease * Neuropathy Grade 3 or more * Previous extensive radiotherapy except limited field RT for locally advanced nasal NK PTCL or for pain palliation * Prior therapy with severely myelotoxic regimens, including autologous and allogenic stem cell transplantation * Prior therapy with HDAC inhibitors (except for CTCL) * Inadequate hematological, hepatic, or renal function